It is with great pleasure that we announce the first edition of “RespiDART: Frontiers in Drug Development against Respiratory Viruses” will be held in Miami, Florida, USA, on November 29 - 30, 2018.
Over the past several decades, the DART conference series have focused on the latest developments in antiviral therapy against viruses such as HIV, hepatitis B and hepatitis C. Just as viruses are ever evolving, the DART series strives to adapt itself to emerging challenges facing today’s global community. Respiratory viruses such as RSV and influenza virus have longed threatened human health, especially in vulnerable populations such as infants, the elderly, and the immune-compromised. Recent outbreaks of emerging threats such as MERS-coV, parainfluenza virus and metapneumovirus have raised alarm across the globe.
By bringing together world leaders and key opinion holders, RespiDART 2018 will address the latest challenges in vaccine and drug development against respiratory viruses. Through mediating rigorous discussions, data sharing, and community building, this meeting aims to identify major clinical and scientific roadblocks, thus paving the way for game-changing scientific advancement.
RespiDART 2018 will focus on topics such as epidemiology and diagnosis, virus-host interactions and virus enzymology, vaccine and immunology, small molecule development, drug resistance and virus evolution. Emphasis will be placed on sharing the latest clinical data for several small molecules currently being tested in humans. Novel drug targets and mechanisms of action will also be heavily explored. Ultimately, “RespiDART 2018” aims to bridge the gap between the latest scientific developments and real world clinical needs. Medical progress against respiratory viruses has been advancing at an inspiring rate. We hope that RespiDART will play an important part in accelerating these developments and we sincerely look forward to your participation in November 2018.
The conference chairs,